Evidence map›Paper›PMID 29667336›Full record

ArticleJournal of the International AIDS Society2018

Optimal breastfeeding durations for HIV-exposed infants: the impact of maternal ART use, infant mortality and replacement feeding risk.

Divya Mallampati, Rachel L MacLean, Roger Shapiro, Francois Dabis, Barbara Engelsmann, Kenneth A Freedberg, Valeriane Leroy, Shahin Lockman, Rochelle Walensky, Nigel Rollins and 1 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. BCG Vaccination and Mother-to-Infant Transmission of HIV.The Journal of infectious diseases · 2020
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Divya MallampatiDepartment of Obstetrics and Gynecology, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-0011-9576
Rachel L MacLeanMedical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Roger ShapiroDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Francois DabisUniversité Bordeaux, Institut de Santé Publique, d'Epidémiologie et de Dévelopement (ISPED), Centre INSERM, U1219-Bordeaux Population Health, Bordeaux, France.
Barbara EngelsmannOrganization for Public Health Interventions and Development, Harare, Zimbabwe.
Kenneth A FreedbergMedical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6471-7930
Valeriane LeroyInserm U1027, University of Toulouse 3, Toulouse, France.
Shahin LockmanDepartment of Immunology and Infectious Diseases, Harvard T.H, Chan School of Public Health, Boston, MA, USA.
Rochelle WalenskyMedical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Nigel RollinsDepartment of Maternal Newborn, Child and Adolescent Health World Health Organization, Geneva, Switzerland.
Andrea CiaranelloMedical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
Innovation across the spectrum of pediatric HIV care: Clinical impact and cost-effectiveness of long-acting antiretroviral therapy for breastfeeding people with HIV and their infants in ZimbabweR01HD079214 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI CIARANELLO, ANDREA LYNNE · 2014 to 2023
$8.0M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR01AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI REDDY, KRISHNA P · 2011 to 2024
$6.8M
Optimizing HIV Care in Less Developed CountriesR37AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FREEDBERG, KENNETH ALAN · 2018 to 2024
$6.6M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR37AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALENSKY, ROCHELLE P. · 2015 to 2019
$3.8M
Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
NIAID NIH HHS K24 AI131928NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI058736NIAID NIH HHS R01 AI093269NIAID NIH HHS R37 AI093269NICHD NIH HHS R01 HD079214World Health Organization 001
6 · The paper itself

Abstract

introductionIn 2010, the WHO recommended women living with HIV breastfeed for 12 months while taking antiretroviral therapy (ART) to balance breastfeeding benefits against HIV transmission risks. To inform the 2016 WHO guidelines, we updated prior research on the impact of breastfeeding duration on HIV-free infant survival (HFS) by incorporating maternal ART duration, infant/child mortality and mother-to-child transmission data.

methodsUsing the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-Infant model, we simulated the impact of breastfeeding duration on 24-month HFS among HIV-exposed, uninfected infants. We defined "optimal" breastfeeding durations as those maximizing 24-month HFS. We varied maternal ART duration, mortality rates among breastfed infants/children, and relative risk of mortality associated with replacement feeding ("RRRF"), modelled as a multiplier on all-cause mortality for replacement-fed infants/children (range: 1 [no additional risk] to 6). The base-case simulated RRRF = 3, median infant mortality, and 24-month maternal ART duration.

resultsIn the base-case, HFS ranged from 83.1% (no breastfeeding) to 90.2% (12-months breastfeeding). Optimal breastfeeding durations increased with higher RRRF values and longer maternal ART durations, but did not change substantially with variation in infant mortality rates. Optimal breastfeeding durations often exceeded the previous WHO recommendation of 12 months.

conclusionsIn settings with high RRRF and long maternal ART durations, HFS is maximized when mothers breastfeed longer than the previously-recommended 12 months. In settings with low RRRF or short maternal ART durations, shorter breastfeeding durations optimize HFS. If mothers are supported to use ART for longer periods of time, it is possible to reduce transmission risks and gain the benefits of longer breastfeeding durations.

Indexed as

Breast FeedingInfant MortalityAnti-HIV AgentsFemaleHIV InfectionsHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalTime FactorsAnti-HIV AgentsbreastfeedingHIVinfant/child healthmaternal healthmodellingPMTCT

Identifiers

PMID29667336
PMCPMC5904528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.